BMO Capital analyst Alex Arfaei came out to defend Merck (NYSE: MRK) which is down 5.9% after the company announced ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE